Amylyx Pharmaceuticals Publishes Data From Weeks 24, 48 Of Its Phase 2 HELIOS Study Of AMX0035 To Treat Wolfram Syndrome; Results Demonstrate Continued Improvements In Pancreatic Beta Cell Function Through Week 48
Amylyx Pharmaceuticals Inc AMLX
$14.06
▲ +0.93%
(+$0.13)
Open
$13.99
Prev Close
$13.93
Day Range
$13.84 – $14.06
52W Range
$4.64 – $18.61
Market Cap
$1.55B
Beta
-0.15
EPS (TTM)
$-1.55
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2022-01-07 |
| Shares Out. | 111,190,000 |
| Website | amylyx.com/ ↗ |
| Phone | 13026365400 |
Amylyx Pharmaceuticals Inc is a publicly traded company under the ticker symbol AMLX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-05-01)
📰 Latest News for AMLX
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
FDA's Makary On Brink: Why Biotech And Pharma Investors Shouldn't Panic (Or Celebrate)
12 Health Care Stocks Moving In Friday's Pre-Market Session